Michael Barbella, Managing Editor02.13.24
Verici Dx plc has signed an exclusive global licensing agreement with Thermo Fisher Scientific to further develop an assay for pre-transplant prognostic testing for early kidney rejection risk.
The exclusive license grants Thermo Fisher the rights to develop and offer an assay for pre-transplant risk assessment as a Laboratory Developed Test (LDT) in its CLIA laboratory in the United States, as well as worldwide rights.
“We are incredibly proud of our advancements in transforming potential outcomes for kidney transplant patients. By collaborating with Thermo Fisher, we believe we can accelerate the development of our technology, helping ensure that it reaches those who need it the most,” Verici Dx CEO Sara Barrington said.
The aim is to develop a test that can risk stratify patients based on their likely immune response to a transplanted kidney and, as a result, enable clinicians to make more informed decisions about post-transplant and immunosuppressive management.
“There is a significant need for effective tests that can identify the risk of transplant rejection early to help inform treatment decisions," stated Nicole Brockway, president, Transplant Diagnostics, Thermo Fisher Scientific. "Our hope is that this licensing agreement will allow us to develop a new prognostic assay that will expand and strengthen our portfolio of transplant testing solutions, demonstrating our commitment to enabling clinicians and improving the lives of patients throughout the pre- and post-transplant journey.”
Verici Dx develops tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence-assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The company also collaborates with medical device, biopharmaceutical, and data science partners.
Thermo Fisher Scientific Inc. ihas annual revenues of more than $40 billion. Its global team delivers a combination of technologies, purchasing convenience, and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
The exclusive license grants Thermo Fisher the rights to develop and offer an assay for pre-transplant risk assessment as a Laboratory Developed Test (LDT) in its CLIA laboratory in the United States, as well as worldwide rights.
“We are incredibly proud of our advancements in transforming potential outcomes for kidney transplant patients. By collaborating with Thermo Fisher, we believe we can accelerate the development of our technology, helping ensure that it reaches those who need it the most,” Verici Dx CEO Sara Barrington said.
The aim is to develop a test that can risk stratify patients based on their likely immune response to a transplanted kidney and, as a result, enable clinicians to make more informed decisions about post-transplant and immunosuppressive management.
“There is a significant need for effective tests that can identify the risk of transplant rejection early to help inform treatment decisions," stated Nicole Brockway, president, Transplant Diagnostics, Thermo Fisher Scientific. "Our hope is that this licensing agreement will allow us to develop a new prognostic assay that will expand and strengthen our portfolio of transplant testing solutions, demonstrating our commitment to enabling clinicians and improving the lives of patients throughout the pre- and post-transplant journey.”
Verici Dx develops tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence-assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The company also collaborates with medical device, biopharmaceutical, and data science partners.
Thermo Fisher Scientific Inc. ihas annual revenues of more than $40 billion. Its global team delivers a combination of technologies, purchasing convenience, and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.